Addiction and the bipolar spectrum: Dual diagnosis with a common substrate?

Addictive Disorders and their Treatment

Volumn 3, Issue 4, 2004, Pages 156-164

  Maremmani, Icro ^a,b,c,e   Pacini, Matteo ^a,b   Perugi, Giulio ^a,b   Akiskal, Hagop S ^d  

^a UNIVERSITY OF PISA   (Italy)

^b G DE LISIO INSTITUTE OF BEHAVIOURAL SCIENCES   (Italy)

^c Assoc Applic Neuroscientific K   (Italy)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

Addiction; Bipolar disoder; Dual diagnosis; Methadone treatment

Indexed keywords

ALCOHOL; CANNABIS; COCAINE; DIAMORPHINE; METHADONE; NALOXONE; NALTREXONE; OPIATE; PSYCHOTROPIC AGENT;

BIPOLAR DISORDER; BORDERLINE STATE; DRUG DEPENDENCE; DYSPHORIA; EUPHORIA; HEROIN DEPENDENCE; HUMAN; HYPERTHERMIA; HYPOMANIA; IMPULSE CONTROL DISORDER; MENTAL DISEASE; METHADONE TREATMENT; NEUROBIOLOGY; OPIATE ADDICTION; PAIN; PRIORITY JOURNAL; PSYCHIATRIST; REVIEW; RISK FACTOR; SELF MEDICATION; SUBSTANCE ABUSE; TREATMENT OUTCOME;

EID: 10644226175     PISSN: 15315754     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.adt.0000134613.28760.2f     Document Type: Review

References (69)

1. A.P.A. DSM-IV. Diagnostic and Statistical Manual of Mental Disorders. Washington: American Psychiatric Association; 1994.
2. Nye RA. The evolution of the concept of medicalization in the late twentieth century. J Hist Behav Sci. 2003;39:115-129.
3. Berridge V. Histories of harm reduction: illicit drugs, tobacco, and nicotine. Subst Use Misuse. 1999;34:35-47.
4. Levine RJ. Medicalization of psychoactive substance use and the doctor-patient relationship. Milbank Q. 1991;69:623-640.
5. Ray L. Problems of substance abuse: exploitation and control. Soc Sci Med. 1985;20:1225-1233.
6. Blum A. Nicotine chewing gum and the medicalization of smoking. Ann Intern Med. 1984;101:121-123.
7. Vuori H. Medicalization of social phenomena. Scand J Soc Med Suppl. 1982;31:95-110.
8. Ludwig AM, Wikler A. "Craving" and relapse to drink. Quart J Stud Alcohol. 1974;35:108-130.
9. Dole VP, Nyswander ME. Heroin addiction: a metabolic disease. Arch Intern Med. 1967;120:19-24.
10. Tagliamonte A. Heroin addiction as normal illness. Heroin Add & Rel Clin Probl. 1999;1:9-12.
11. Rozin P, Stoess C. Is there a general tendency to become addicted? Addict Behav. 1993;18:81-87.
12. Khantzian EJ, Treece C. DSM-III psychiatric diagnosis of narcotic addicts: recent findings. Arch Gen Psychiatry. 1985;42:1067-1077.
13. Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259-1264.
14. Maremmani I, Zolesi O, Daini L, et al. Disturbi Correlati a Sostanze. Oppiacei. In: Cassano GB, Pancheri P, Pavan L, et al, eds. Trattato Italiano di Psichiatria. Milano: Masson; 1999:1352-1377.
15. Verebey K. Opioids in Mental Illness: Theories, Clinical Observations and Treatment Possibilities. New York: The New York Academy of Sciences; 1982.
16. Perugi G, Akiskal HS. The soft bipolar spectrum redefined: focus on the cyclothymic anxious-sensitive, impulse discontrol, and binge-eating connection in bipolar II and related conditions. Psychiatric Clin North Am. 2002;25:713-737.
17. Akiskal HS, Mallya G. Criteria for the "soft" bipolar spectrum: treatment implications. Psychopharmacol Bull. 1987;23:68-73.
18. Akiskal HS, Djenderedjian AM, Rosenthal RH. Cyclothymic disorder: validating criteria for inclusion in the bipolar affective group. Am J Psychiatry. 1977;134:1227-1233.
19. Akiskal HS. Subaffective disorders: dysthymic, cyclothymic and bipolar II disorders in the "borderline" realm. Psychiatr Clin North Am. 1981;4:25-46.
20. Akiskal HS, Judd LL, Gillin JC, et al. Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms. J Affect Disord. 1997;45:53-63.
21. Cassano GC, Akiskal HS, Savino M, et al. Proposed subtype of bipolar II disorder with hypomanic episodes (or cyclothymia) and with hyperthymic temperament. J Affect Disord. 1992;26:127-140.
22. Cassano GB, Savino M, Perugi G, et al. Major depressive episode: unipolar and bipolar II. Encephale. 1992;18(Spec No 1):15-18.
23. Judd LL, Schettler PJ, Akiskal HS. The prevalence, clinical relevance and public health significance of subthreshold depressions. Psychiat Clin North Am. 2002;25:685-698.
24. Weiss RD, Mirin SM. Tricyclic antidepressants in the treatment of alcoholism and drug abuse. J Clin Psychiatry. 1989;50: Suppl:4-9; discussion 9-11.
25. Miller FT, Busch F, Tanenbaum JH. Drug abuse in schizophrenia and bipolar disorders. Am J Drug Alcohol Abuse. 1989;15:291-295.
26. Goldberg JF, Garno JL, Portera L, et al. Correlates of suicidal ideation in dysphoric mania. J Affect Disord. 1999;56:75-81.
27. Freed EX. Alcohol abuse by manic patients. Psychological Report. 1969;25:280.
28. Dunner DL, Hensel BM, Fieve RR. Bipolar illness: factors in drinking behavior. Am J Psychiatry. 1979;136:583-585.
29. Hensel B, Dunner DL, Fieve RR. The relationship of family history of alcoholism to primary affective disorder. J Affect Disord. 1979;1:105-113.
30. Estroff TW, Dackis CA, Gold MS, et al. Drug abuse and bipolar disorders. Int J Psychiatry Med. 1985;15:37-40.
31. Bernadt MW, Murray RM. Psychiatric disorder, drinking and alcoholism: what are the links? Br J Psychiatry. 1986;148:393-400.
32. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiological Catchment Area (ECA) study. JAMA. 1990;264:2511-2518.
33. Maremmani I, Canoniero S, Pacini M. Methadone dose and retention in treatment of heroin addicts with bipolar I disorder comorbidity. Preliminary results. Heroin Add & Rel Clin Probl. 2000;2:39-46.
34. Maremmani I, Canoniero S, Pacini M, et al. Opioids and cannabinoids abuse among bipolar patients. Heroin Add & Rel Clin Probl. 2000;2:35-42.
35. Strakowski SM, Sax KW, Setters MJ, et al. Lack of enhanced response to repeated d-amphetamine challenge in first-episode psychosis: implications for a sensitization model of psychosis in humans. Biol Psychiatry. 1997;42:749-755.
36. Winokur G, Turvey C, Akiskal HS, et al. Alcoholism and drug abuse in three groups; bipolar I, unipolars and their acquaintances. J Affect Disord. 1998;50:81-89.
37. Helzer JE, Pryzbeck TR. The co-occurrence of alcoholism with other psychiatric disorders in the general population and its impact on treatment. J Stud Alcohol. 1988;49:219-224.
38. Dorus W, Senay EC. Depression demographic dimensions, and drug abuse. Am J Psychiatry. 1980;137:669-704.
39. Lehman WX, De Angelis GC. Adolescents, methadone and psychotherapeutic agents. In: N.A.P.A.N., eds. Proceedings of the IV National Conference on Methadone Treatment. New York: The Association; 1972.
40. Robins PR. Depression and drug addiction. Psychoanal Q. 1974;48:375-386.
41. Rounsaville BJ, Weissman MM, Rosenberger PH, et al. Detecting depressive disorders in drug abusers: a comparison of screening instruments. J Affect Disord. 1979;1:255-267.
42. Senay EC. Multimodality programming in Illinois: evolution of a public health concept. In: Lowinson JH, Ruiz P, eds. Substance Abuse: Clinical Problem and Perspectives. Baltimore, MD: Williams and Wilkins; 1981:365-382.
43. Steer RA, Kotzer E. Affective changes in male and female methadone patients. Drug Alcohol Depend. 1980;5:115-122.
44. Weissman MM, Slobetz F, Prusoff BA, et al. Clinical depression among narcotic addicts maintained on methadone in the community. Am J Psychiatry. 1976;133:1434-1438.
45. Wieland WF, Sola S. Depression in opiate addicts measured by objective tests. In: Proceedings of the III National Conference on Methadone Treatment. New York: AMTA; 1970:187-202.
46. Mason BJ, Kocsis JH, Melia D, et al. Psychiatric comorbidity in methadone maintained patients. J Addict Dis. 1998;17:75-89.
47. Mirin SM, Weiss R, Michael J, et al. Psychopathology in substance abusers: diagnosis and treatment. Am J Drug Alcohol Abuse. 1988;14:139-157.
48. Mirin SM, Weiss RD. Psychiatric comorbidity in drug/alcohol addiction. In: Miller NS, ed. Comprehensive Handbook of Drug and Alcohol Addiction. White Plains, NY: Mercel Dekker, Inc; 1991:65-77.
49. Rounsaville BJ, Weissman MM, Crits-Christoph K, et al. Diagnosis and symptoms of depression in opiate addicts. Course and relationship to treatment outcome. Arch Gen Psychiatry. 1982;39:151-156.
50. Maremmani I, Zolesi O, Aglietti M, et al. Methadone dose and retention in treatment of heroin addicts with Axis I psychiatric comorbidity. J Addict Dis. 2000;19:29-41.
51. Maremmani I, Capone MR, Aglietti M, et al. Heroin dependence and bipolar disorders. New Trends Exper Clin Psychiatry. 1994;179-182.
52. Maremmani I, Lazzeri A, Lovrecic M, et al. Diagnostic and symptomatological features in chronic psychotic patients according to cannabis use status. J Psychoactive Drugs. (In press)
53. Martin WR, Jasinski DR, Mansky PA. Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry. 1973;28:784-791.
54. Resnick RB, Schuyten E, Cooper L, et al. Narcotic Antagonists: A Point of View Concerning Treatment Approaches. Rockville: NIDA; 1974.
55. Sideroff SN, Charauwasta VC, Farvik ME. Craving in heroin addicts maintained on the opiate antagonist naltrexone. Am J Drug Alcohol Abuse. 1978;5:415-423.
56. Perugi G, Frare F, Madaro D, et al. Alcohol abuse in social phobic patients: is there a bipolar connection? J Affect Disord. 2002;68:33-39.
57. Perretta P, Akiskal HS, Nisita C, et al. The high prevalence of bipolar II and associated cyclothymic and hyperthymic temperaments in HIV-patients. J Affect Disord. 1998;50:215-224.
58. Placidi GF, Signoretta S, Liguori A, et al. The semi-structured affective temperament interview (TEMPS-I). Reliability and psychometric properties in 1010 14-26-year-old students. J Affect Disord. 1998;47:1-10.
59. Perugi G, Toni C, Travierso MC, et al. The role of cyclothymia in atypical depression: toward a data-based reconceptualization of the borderline-bipolar II connection. J Affect Disord. 2003;73:87-98.
60. Maremmani I, Pacini M, Lubrano S, et al. Dual diagnosis heroin addicts. The clinical and therapeutic aspects. Heroin Add & Rel Clin Probl. 2003;5:7-98.
61. Welch SS, Linehan MM. High-risk situations associated with parasuicide and drug use in borderline personality disorder. J Personal Disord. 2002;16:561-569.
62. Silberman EK, Reus VI, Jimerson DC, et al. Heterogeneity of amphetamine response in depressed patients. Am J Psychiatry. 1981;138:1302-1307.
63. Verebey KE. Opioids in Mental Illness: Theories, Clinical Observations and Treatment Possibilities. The New York Academy of Sciences, New York, NY.
64. Extein I, Pickard D, Gold MS, et al. Methadone and morphine in depression. Pharmacol Bull. 1981;17:29-33.
65. Mc Kenna GJ. Methadone and opiate drugs: psychotropic effect and self-medication. In: Verebey K, ed. Opioids in Mental Illness: Theories, Clinical Observations and Treatment Possibilities. New York: The New York Academy of Sciences; 1982:33-43.
66. The use of methadone as a psychotropic agent. Nat Conf Methadone Treat Proc. 1973;5:1317-1324.
67. Maremmani I, Zolesi O, Agueci T, et al. Methadone doses and psychopathological symptoms during methadone maintenance. J Psychoactive Drugs. 1993;25:253-263.
68. Pani PP, Agus A, Gessa GL. Methadone as a mood stabilizer. [Letter] Heroin Add & Rel Clin Probl. 1999;1:43-44.
69. Levinson I, Rosenthal RN. Methadone withdrawal psychosis. J Clin Psychiatry. 1995;56:73-76.